Pig Defensin Peptides as Natural Antibiotics: From Swine Health to Potential Human Medicine | Research

The takeaway

Porcine β-defensins combine antimicrobial and immunomodulatory properties that can be enhanced through diet and gene editing, offering translational opportunities for both veterinary and human medicine.

Defensins enhanced by both diet and gene editing
Porcine β-defensin production can be boosted through dietary supplementation and genetic engineering, providing two complementary strategies for reducing antibiotic dependency in one of the world's largest meat industries

What the researchers found

The review establishes that porcine β-defensins (pBDs) have dual functionality: direct antimicrobial activity against a range of pathogens and immunomodulatory properties that enhance the broader immune response. Two approaches to enhancing pBD expression have shown promise: dietary supplementation (specific feed components can upregulate defensin production) and gene editing techniques in pigs and porcine cell models.

The biological roles of pBDs extend beyond simple pathogen killing to include immune cell recruitment, modulation of inflammatory responses, and coordination of adaptive immunity. Clinical trials in swine have validated their efficacy in infection control, supporting their potential as prophylactic and therapeutic alternatives to conventional antibiotics in both veterinary and translational medicine.

Why it matters

Antibiotic use in livestock farming is a major driver of antimicrobial resistance, and the agricultural sector consumes more antibiotics globally than human medicine. Enhancing natural defensin production in pigs through diet or genetics could dramatically reduce antibiotic dependency in pork production — one of the largest meat industries worldwide. The translational angle is equally important: pigs are physiologically similar to humans, making porcine defensin research directly relevant to developing antimicrobial peptide therapies for people.

How the study worked

This is a comprehensive narrative review (state-of-the-art) synthesizing research on porcine β-defensins from in vitro characterization through animal trials and clinical applications. It covers molecular biology, immunology, nutrition, and gene editing approaches to defensin enhancement.

What this study cannot tell us

As a review focused on porcine systems, direct human applicability requires further investigation. The gene editing approaches face regulatory and public acceptance challenges. Dietary enhancement of defensin expression may vary with pig genetics, age, and health status. The review does not quantify the degree of antimicrobial activity or compare it to antibiotic efficacy in standardized terms. Long-term effects of enhanced defensin expression (potential autoimmune or inflammatory consequences) are not addressed.

How to read the evidence

This is a comprehensive narrative review synthesizing in vitro, animal model, and clinical trial evidence from the porcine defensin field. The breadth of evidence cited is strong, but individual studies vary in quality and the review format does not systematically assess bias.

When this study was published

Published in 2025, this is a very recent review capturing the current state of porcine defensin research, including recent advances in gene editing technology.

The bigger picture

The One Health approach recognizes that animal, human, and environmental health are interconnected. Reducing antibiotic use in livestock through defensin enhancement addresses antimicrobial resistance at its source. Porcine defensins also serve as a bridge to human medicine — pigs are used as models for human disease, and their defensin biology closely parallels human β-defensins. The gene editing approaches described could eventually be applied to create disease-resistant pig lines that rarely need antibiotics, while the peptides themselves could be developed as therapeutic agents.

Questions still open

Could dietary defensin enhancement in pigs be standardized enough to reliably replace prophylactic antibiotics in commercial farming?
Which porcine β-defensin genes are most promising as therapeutic candidates for human infection treatment?
Would gene-edited pigs with enhanced defensin expression show improved disease resistance without compromising growth performance or meat quality?

Common questions

What are defensins and why are they important for farming?

Defensins are small antimicrobial peptides that animals naturally produce as part of their immune defense. In pigs, β-defensins kill bacteria, modulate the immune system, and help control infections. By boosting defensin production through diet or gene editing, farmers could reduce their reliance on antibiotics — a critical goal since antibiotic use in livestock is a major contributor to the drug-resistant 'superbugs' that threaten human health.

Could pig defensins lead to new antibiotics for humans?

Potentially, yes. Pig and human immune systems share many features, and porcine β-defensins are structurally similar to human β-defensins. Research on these pig peptides provides insights into how defensins work, which peptide variants are most effective, and how their production can be enhanced — knowledge directly applicable to developing antimicrobial peptide therapies for human infections, particularly antibiotic-resistant ones.

Read the original research

Piggybacking on nature: exploring the multifaceted world of porcine β-defensins.

Veterinary research, 56(1), 47

View on PubMed ↗Publisher’s paper ↗

Citation

Finatto, Arthur Nery; Meurens, François; de Oliveira Costa, Matheus. (2025). Piggybacking on nature: exploring the multifaceted world of porcine β-defensins.. Veterinary research, 56(1), 47. https://doi.org/10.1186/s13567-025-01465-4